Innovative Osteosarcoma Treatments and Expansive Market Reach: Interview with OS Therapies' CEO
Aug. 5, 2024
OS Therapies (OSTX), a clinical stage biopharmaceutical company, is at the forefront of
developing innovative treatments for Osteosarcoma (OS), breast cancer and other
solid tumors. With a dedicated focus on addressing the unmet need for new cancer
treatments in children and young adults, the company is making significant strides
in tackling the complexities of OS, a rare but aggressive bone cancer predominantly
affecting individuals under 40 years of age.
The company's primary initiative revolves around its lead product candidate, OSTHER2 (OST31-164), which is poised to revolutionize the treatment landscape for OS,
breast cancer, and other HER2 expressing cancers. This innovative immunotherapy
leverages a genetically modified strain of Listeria monocytogenes to specifically
target cancer cells that express HER2 p, a promising approach in the fight against
cancer that is complementary to HER2 antibody therapy such as Herceptin®.
Notably, OST-HER2 is distinct in the current landscape, as there have been no new
treatments approved by the FDA for OS in over 40 years.
In addition to OST-HER2, OS Therapies is expanding its impact with the OST-Tunable
Antibody Drug Conjugate (OST-tADC) platform. This cutting-edge technology
represents a next-generation approach in antibody-drug conjugates (ADCs),
featuring tunable pH-sensitive silicone linkers (SiLinkers™) and the potential to
deliver a range of payloads, including antibodies, chemotherapeutics, and mRNA
treatments. The OST-tADC platform is being developed to target solid tumors.
